

Supplementary material

Ślawiński G, Zieleniewicz P, Młyński M, et al. Optimal hospital discharge time after CIED implantation: A retrospective study from a reference electrotherapy center. Kardiol Pol. 2023.

Please note that the journal is not responsible for the scientific accuracy or functionality of any supplementary material submitted by the authors. Any queries (except missing content) should be directed to the corresponding author of the article.

Table S1. The descriptive characteristics of the study group, divided into patients without complications and with complications

Variable	Study group (n = 416)	Patients without complications (n = 383)	Patients with complications (n = 33)	P-value
Sex, men; n (%)	261 (62.7%)	241 (62.9%)	20 (60.6%)	0.79
Age, years; mean (SD)	70.1 (14.4)	70.3 (14.3)	73 (15.8)	0.47
BMI; mean (SD)	28.2 (5.3)	28.2 (5.4)	28.2 (4.5)	0.93
Comorbidities:				
HF; n (%)	226 (54.3%)	202 (52.7%)	24 (72.7%)	0.03
HF _r EF; n (%)	129 (31%)	115 (30.0%)	14 (42.4%)	0.14
HF _{mr} EF; n (%)	55 (13.2%)	49 (12.8%)	6 (18.2%)	0.38
HF _{pe} EF; n (%)	42 (10.1%)	38 (9.9%)	4 (12.1%)	0.69
AF; n (%)	212 (51%)	197 (51.4%)	15 (45.5%)	0.52
Hypertension; n (%)	278 (66.8%)	258 (67.4%)	20 (60.6%)	0.43
CAD; n (%)	197 (47.4%)	175 (45.7%)	22 (66.7%)	0.02
Diabetes type 2; n (%)	127 (30.5%)	118 (30.8%)	9 (27.3%)	0.68
Stroke/TIA; n (%)	51 (12.3%)	45 (11.7%)	6 (18.2%)	0.27
CKD; n (%)	85 (20.4%)	75 (19.6%)	10 (30.3%)	0.14
Active cancer; n (%)	10 (2.4%)	10 (2.6%)	0	0.35
LVEF, % mean (SD)	46.4 (15.0)	46.8 (14.9)	41.9 (15.8)	0.07

Charlson Comorbidity Index; median (IQR)	2 (1-4)	2 (1-4)	2 (1-4)	0.49
Age-adjusted Charlson Comorbidity Index; median (IQR)	5 (4-7)	5 (4-7)	5 (4-7)	0.76
Procedure variables:				
De novo implantation; n (%)	325 (78.1%)	303 (79.1%)	22 (66.7%)	0.10
Upgrade procedure; n (%)	91 (21.9%)	80 (20.9%)	11 (33.3%)	0.10
Planned hospitalization; n (%)	142 (34.1%)	133 (34.7%)	9 (27.3%)	0.39
Urgent hospitalization; n (%)	274 (65.9%)	250 (65.3%)	34 (72.7%)	0.39
Pacemaker; n (%)				
VVI system; n (%)	268 (64.4%)	251 (65.5%)	17 (48.5%)	0.11
DDD system; n (%)	33 (7.9%)	32 (8.4%)	1 (3.0%)	0.27
CRT-P system; n (%)	188 (45.2%)	175 (45.7%)	13 (39.4%)	0.49
T-ICD; n (%)	47 (11.3%)	44 (11.5%)	3 (9.1%)	0.68
VR system; n (%)	119 (28.6%)	104 (27.2%)	15 (45.4%)	0.03
DR system; n (%)	31 (7.5%)	30 (7.8%)	1 (3.0%)	0.31
CRT-D system; n (%)	22 (5.3%)	18 (4.7%)	4 (12.1%)	0.07
S-ICD; n (%)	66 (15.9%)	56 (14.6%)	10 (30.3%)	0.02
Temporary transvenous pacemaker; n (%)	29 (7%)	28 (7.3%)	1 (3%)	0.35
Semi-permanent pacemaker; n (%)	18 (4.3%)	16 (4.2%)	2 (6.1%)	0.61
Indications for the procedure:				
AVB; n (%)	6 (1.4%)	6 (1.6%)	0	0.46
SSS; n (%)				
SSS+AVB; n (%)				
Primary prevention of SCD; n (%)	144 (34.6%)	137 (35.8%)	7 (21.2%)	0.09
Secondary prevention of SCD; n (%)	87 (21%)	80 (20.9%)	7 (21.2%)	0.97
HF; n (%)	18 (4.3%)	17 (4.4%)	1 (3.0%)	0.70
Other; n (%)	57 (13.7%)	54 (14.1%)	3 (9.1%)	0.42

	46 (11.1%)	41 (10.7%)	5 (15.2%)	0.43
	63 (15.1%)	54 (14.1%)	9 (27.3%)	0.04
	1 (0.2%)	0	1 (3.0%)	0.56
Laboratory tests:				
Creatinine, mg/dL; median (Q1-Q3)	1.0 (0.8-1.2)	1.0 (0.8-1.2)	1.1 (0.9-1.3)	0.23
CRP, mg/L; median (Q1-Q3)	3.1 (1.2-8.4)	3.1 (1.3-8.5)	2.0 (1.0-5.0)	0.09
BNP, pg/mL; median (Q1-Q3)	168.0 (63.0-402.0)	165.0 (61.0-366.0)	197.0 (100.0-787.0)	0.09
NT-proBNP, pg/mL; median (Q1-Q3)	1091.5 (467.0-3142.0)	1146.0 (479.0-3158.0)	850.0 (169.0-2161.0)	0.44
Platelets, x10 ⁹ ; median (Q1-Q3)	210.0 (169.0-259.0)	209.0 (169.0-259.0)	218.0 (169.0-253.0)	0.86
Anticoagulation and antiplatelet therapy:				
VKA; n (%)	34 (8.2%)	31 (8.1%)	3 (9.4%)	0.79
NOAC; n (%)	145 (34.9%)	133 (34.7%)	12 (37.5%)	0.75
LMWH; n (%)	62 (15.0%)	59 (15.4%)	3 (9.4%)	0.35
ASA; n (%)	124 (29.9%)	110 (28.7%)	14 (43.8%)	0.07
Clopidogrel; n (%)	39 (9.4%)	35 (9.1%)	4 (12.5%)	0.52
Ticagrelor; n (%)	15 (3.6%)	13 (3.4%)	2 (6.3%)	0.39

Abbreviations: AF – atrial fibrillation; ASA – acetylsalicylic acid; AVB – atrioventricular block; BMI – body mass index; BNP – B-type natriuretic peptide; CAD – coronary artery disease; CKD – chronic kidney disease; CRP – C-reactive protein; CRT – cardiac resynchronization therapy; HF – heart failure; HFmrEF – heart failure with mid-range ejection fraction; HFpEF – heart failure with preserved ejection fraction; HFrEF – heart failure with reduced ejection fraction; NOAC – novel oral anticoagulants; LMWH - Low molecular weight heparin; LVEF – left ventricular ejection fraction; NT-proBNP - N-terminal pro-B-type natriuretic peptide; SCD – sudden cardiac death; S-ICD – subcutaneous

implantable cardioverter-defibrillator; SSS – sick sinus syndrome; TIA - transient ischemic attack; T-ICD – transvenous implantable cardioverter-defibrillator; VKA – vitamin K antagonist

Table S2. Univariate and multivariable analysis of predictors of complications after CIED procedures

Variable	Univariate analysis			Multivariable analysis		
	OR	95% CI	<i>P</i> -value	OR	95% CI	<i>P</i> -value
Chronic heart failure	2.41	1.09-5.33	0.03	2.19	0.98-4.92	0.06
Coronary artery disease	2.38	1.12-5.04	0.02	2.26	1.06-4.79	0.03
C-reactive protein concentration	0.96	0.91-1.02	0.09	0.94	0.88-1.00	0.08
Upgrade procedure	1.89	0.88-4.07	0.10			